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Retroviral vectors are potent tools for gene delivery and various biomedical applications. To accomplish a gene transfer task
successfully, retroviral vectors must effectively transduce diverse cell cultures at different phases of a cell cycle. However, very
promising retroviral vectors based on the foamy viral (FV) backbone lack the capacity to efficiently transduce quiescent cells. It is
hypothesized that this phenomenon might be explained as the inability of foamy viruses to form a pre-integration complex (PIC)
with nuclear import activity in growth-arrested cells, which is the characteristic for lentiviruses (HIV-1). In this process, the HIV-1
central polypurine tract (cPPT) serves as a primer for plus-strand synthesis to produce a “flap” element and is believed to be crucial
for the subsequent double-stranded cDNA formation of all retroviral RNA genomes. In this study, the effects of the lentiviral cPPT
element on the FV transduction potential in dividing and growth-arrested (G
1
/S phase) adenocarcinomic human alveolar basal
epithelial (A549) cells are investigated by experimental and theoretical methods.The results indicated that the HIV-1 cPPT element
in a foamy viral vector background will lead to a significant reduction of the FV transduction and viral titre in growth-arrested cells
due to the absence of PICs with nuclear import activity.
1. Introduction
Retroviral vectors are efficient gene transfer vehicles that
deliver transgenes by integration of the viral genome into the
genome of host cells. This remarkable ability has been widely
exploited for many biomedical applications, including gene
therapy. In order to replicate, all retroviruses pursue a very
complex process, which is known as reverse transcription.
During this event, they transcribe their single-stranded RNA
genomes into double-stranded complementary DNA (ds
cDNA) prior to its integration into the host genome [1, 2].The
outcome of reverse transcription is a linear DNA with long
terminal repeats (LTRs) at the 3󸀠 and 5󸀠 ends of the viral
genome. As an example, lentiviruses (HIV-1) have evolved
into new forms with a complex reverse transcription strategy
including a strand displacement event controlled by the
central polypurine tract (cPPT), which serves for plus-strand
initiation and priming [3, 4].
The HIV-1 reverse transcription produces a linear DNA
molecule bearing a “peculiar formation,” known as the central
DNA flap element, because the reverse transcription complex
stops at the central termination sequence (CTS) (Figure 1(a)).
This flap element is believed to be essential for a preintegra-
tion complex (PIC) assembly, which is composed of both viral
and cellular proteins [5–7] and possess the ability to cross the
nuclear pore to enter the nucleus. It was previously reported
that some constituents of PIC, such as the viral matrix
protein, contained a nuclear localization signal (NLS) for
PIC-mediated nuclear import [8, 9]. However, the detailed
mechanisms of this process are not yet fully elucidated.
The other retroviruses, such as foamy viruses (FV), have
a replication strategy and probably a PIC formation mecha-
nism different from that present in lentiviruses. FVs belong
to the Spumavirinae retroviral subfamily and are known
as nonpathogenic retroviral species, which are endemic to
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Figure 1: Different reverse transcription outcomes in lenti- (a) and foamy viruses (b). cPPT and CTS abbreviations stand for the central
polypurine tract and central termination sequence, respectively.
a number of mammalians such as non-human primates, cats,
and cows [10].
The genomic organization of the FVs, including the
prototype foamy virus (PFV), which is a molecular cloned
simian foamy virus SFVcpz(hu), is similar to that of other
complex retroviruses, with several additional open reading
frames located in 3󸀠 of the canonical Gag, Pol, and Env genes,
including the transcriptional transactivator gene (tas) [11–15].
The foamy viruses have a very broad host range and infect
a variety of cell lines, including fibroblastoid, epithelioid, and
lymphatic lineages [16]. There are currently a few cell lines
that are resistant to FV infection, such as the zebrafish PAC2
and human erythroid precursor cell lines [17]. FV infection
leads to massive cell death via apoptosis in vitro and without
any overt pathogenic effect in vivo [18].
Essentially, foamy viruses seem to have diverse outcomes
for the plus-strand priming events in contrast to lentiviruses.
In FV reverse transcription, the strong stop plus-strand DNA
is displaced by DNA elongating from cPPT. This DNA can
further be transferred to the 3󸀠 end of the minus-strand DNA
or serve as a template for synthesis of a double-stranded LTR.
Consequently, cPPT is degraded after completion of the
minus-strand cDNA synthesis producing a single-stranded
gap (Figure 1(b)) [19–21].
There are a number of FV-based vectors for gene therapy
that have been developed [22–24].These constructs have sev-
eral desirable properties in comparison to lentiviral vectors.
The main characteristics of foamy viral vectors are (i) safety:
FVs have not been linked to any established pathology [18,
25]; (ii) wide tissue tropism [10, 26–28]; (iii) viral particles
stable and resilient to ultracentrifugation [29]; (iv) packaging
efficacy for foreign DNA that is at least 9 kb and offers a
valuable tool for the transfer of long genetic elements and
therapeutic transgenes [30]; (v) potential for production of
high-titre FV vectors suitable for ex vivo gene therapy
applications [24, 30, 31].
However, these very promising foamy viral vectors have
one limitation in their ability to efficiently transduce ter-
minally differentiated and growth-arrested mammalian cells
[32] potentially because of their mitosis-dependent integra-
tion [22] and the deficiency in forming PICs with nuclear
import activity from the absence of the lentivaral cPPT
element and central termination sequence.
Therefore, the role of HIV-1 cPPT on FV replication and
its mechanism of action is still to be determined. To pursue
this goal, the transduction rates of cPPT (HIV-)modified
FV vectors in dividing and growth-arrested adenocarcinomic
human alveolar basal epithelial (A549) cells were accessed
along the investigation of underlying molecular mechanisms
and evaluation of their potential for FV-based gene therapy.
2. Materials and Methods
Recombinant DNA techniques: standard molecular cloning
techniques were used for the generation of constructs [33]. A
series of plasmid cloning vectors were preceded by the letter
“p”. In brief, the pUC19-based intermediate was first gener-
ated by ligating a 1.259 kb EcoRI-KpnI fragment from pMD9
(9.940 kb) with a 2.674 kb EcoRI-KpnI fragment from the
pUC19 vector to use the proper restriction sites. Then, four
pUC19-based plasmids, such as pUC19-cPPT (HIV)-CTS,
pUC19-cPPT (PFV)-CTS, pUC19-cPPT (HIV), and pUC19-
CTS, were generated by PCR amplification and insertion of
the fragments bearing the viral structural elements (Table 1)
using relevant oligonucleotides (Table 2) with MfeI-StuI
restriction sites. The lentiviral pWPXL vector (10.510 kb) was
used as a template for the cPPT (HIV), cPPT (HIV)-CTS,
and CTS amplifications. All pMD9-based FV vectors con-
tained the gene encoding enhanced green fluorescent protein
(eGFP) under the control of a constitutively active heterolo-
gous retroviral U3 promoter to enable the quantification of
vector transfer rates (Figure 2).
Cell transfection and purification of supernatant: human
embryonic kidney (HEK 293T) cells [34] were seeded in 2 ×
106 density into 6 cm dishes a day before the transfection.
The cells were transfected with plasmid DNA using a poly-
ethyleneimine transfection reagent (Polysciences Europe
GmbH, Eppelheim, Germany) [35]. The PFV transfection
mixture contained 2.5𝜇g of modified pMD9 vectors, 1.25 𝜇g
of pCIgag2, 0.5𝜇g of pCpol-2, and pCenv-1 packaging plas-
mids [35]. The HIV transfection system contained 2.5𝜇g of
pWPXL, 1.9 𝜇g of psPAX2, and 0.8 𝜇g of pMD2.G (VSV-G)
vectors (gifts from Professor Didier Trono), respectively. The
pMD9 plasmid without Env (pMD9-w/oEnv) and pcDNA
(Invitrogen GmbH, Karlsruhe, Germany) as an empty vector
were used as negative controls without a production of viral
particles. One day after transfection, the cellular transcription
was induced by addition of 10mM sodium butyrate for
8 hrs [36]. After two days, the supernatant was harvested,
passed through a 0.45𝜇mfilter (MerckMillipore, Darmstadt,
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Table 1: Sequences of the viral structural elements used in the construction of modified expression vectors.
Element Length (bp) Sequence
cPPT (PFV) 9 AGGAGAGGG
cPPT (HIV) 33 ATCCACAATTTTAAAAGAAAAGGGGGGATTGGG
CTS 16 AAAAATTCAAAATTTT
Table 2: Forward and reverse primers for a PCR amplification of the fragments used in the construction of modified expression vectors.
Fragments Primers
cPPT (PFV)-CTS 5
󸀠-TATACAATTGCAGGAGAGGGATTGGGGGGTACAGTGCAG-3󸀠
5󸀠-TATAAGGCCTCTGTCCCTGTAATAAACC-3󸀠
cPPT (HIV)-CTS 5
󸀠-TATACAATTGATGGCAGTATCCAC-3󸀠
5󸀠-TATAAGGCCTCTGTCCCTGTAATAAACC-3󸀠
cPPT (HIV) 5
󸀠-TATACAATTGATGGCAGTATCCAC-3󸀠
5󸀠-TATAAGGCCTGTAATTTGTTTTTGTAATTCT-3󸀠
CTS 5
󸀠-TATATACAATTGGGGGGTACAGTGCAGGGG-3󸀠
5󸀠-TATATAAGGCCTTCCCTGTAAACCCGAAAATTTTG-3󸀠
Germany), and layered onto 6mL of sucrose cushion (20%
in DMEM). The supernatant was centrifuged in a SureSpin
630 rotor (Thermo Scientific, Sorvall, Waltham, MA, USA)
at 25000 r.p.m at 4∘C for 3 hrs.
Cell transduction and cell cycle experiments: after clarifi-
cation, the vector-containing supernatants from HEK 293T
cells were functionally assayed to transduce the A549 cell-
line, whichwere incubatedwith them for two days at different
conditions.The conditions were created in the experiment to
test the generated pMD9-based plasmids to efficiently trans-
duce dividing and nondividing cells (G
1
/S phase of a cell
cycle): in Dulbecco’s modified Eagles medium (DMEM) as a
control, in the presence of dimethyl sulfoxide (DMSO), and in
the presence of aphidicolin (Figure 3). The drug was
purchased from Sigma-Aldrich (Germany Sigma-Aldrich
Chemie GmbH, Germany) as a potent antiviral, antimitotic
agent, and DNA polymerase inhibitor, which is used to stop
a cell cycle at G
1
/S phase. The drug was dissolved in pure
DMSO and added to cells at 5 𝜇g/mL concentration for 24 hrs
[32]. The final concentration of DMSO was approximately
0.1% in the medium.
Immunoblotting of viral proteins: analysis of viral protein
expression was done essentially as described elsewhere [37].
In brief, the lysates were prepared from the partially purified
vector supernatant and from transfected cells by suspension
in a detergent-containing buffer. Viral proteins were reacted
with anti-Gag [23] and anti-Pol [38] mouse monoclonal
antibodies (mAbs) after separation in 8% SDS-PAGE and
semidry blotting onto Hybond ECL membranes (Amersham
Pharmacia Biotech, Freiburg, Germany). Protein bands were
detected by using horseradish peroxidase-coupled secondary
antibodies (Dako, Hamburg, Germany) and employing the
enhanced chemiluminescence detection system (Amersham
Pharmacia Biotech, Freiburg,Germany).The ImageJ software
(National Institute of Health, Bethesda, MD, USA) was used
to analyse quantitatively the immunoblotting results.
Vector transfer technique: after clarification, the vector-
containing supernatants were also assayed functionally by
transfer to 1.5 × 104 recipient A549 cells purchased from
American Type Culture Collection (ATCC, Manassas, VA,
USA).The expression of eGFP per 104 cells was monitored by
flow cytometry (FCM) for 48 hrs after the transduction. The
vector transfer assays were repeated at least three times.
Viral transduction dynamics and viral titre prediction:
the MATLAB R2012a software (MathWorks, Natick, MA,
USA) was used to predict the viral transduction dynamics
(𝑓(𝑥)td) and viral titre (𝑓(𝑥)vt) for the analysed plasmids.
Sigmoid dose-response logistic function was implemented in
the MATLAB script M-files using the following equations:
𝑓(𝑥)td =
0.01𝑎
0.01 + 𝑒
(−𝑏𝑥)
, (1)
𝑓(𝑥)vt =
𝑎
0.01 + 𝑒
𝑥
, (2)
where 𝑥 is any independent variable described by linspace
function; 𝑎 is a transduction rate (percentage of eGFP cells); 𝑒
is an exponential constant (𝑒 = 2.718); and 𝑏 integer is a
Hill Slope. The linspace function (𝑥 = linspace(0, 48)) was
used to generate linearly spaced vectors for 48-hour interval
curve. The 𝑏 integer (𝑏 = 0.21) was adjusted to the 𝑓(𝑥)td
logistic function for pWPXL (𝑦
1
= 1./(0.01 + exp(−𝑥. ∗
0.21))) as a reference curve reaching the upper plateau level
with maximal effect after 48 hrs (Supplementary Material 1
in Supplementary Material available online at http://dx.doi
.org/10.1155/2014/487969). To determine the viral titre dyna-
mics, seven dilutions were inspected in the range from the
highest (0.1) to the lowest (10−7) concentrations of the virus
(𝑥 = linspace(0, 6)).
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Figure 2: The structural elements of pWPXL and pMD9 parental plasmid backbones are shown: long terminal repeat (LTR) with U3, R,
and U5 regions, ref-responsive element (RRE), human elongation factor alpha promoter (EF1-𝛼), gene encoding enhanced green fluorescent
protein (eGFP), enhancer/promoter of the human cytomegalovirus immediate early gene (CMV), cis-acting sequences (CASI and CASII),
constitutively active spleen focus forming virus U3 promoter (SFFV U3), and internally deleted U3 region of the 3󸀠 LTR (ΔU3). Foamy viral
cPPT was replaced with cPPT (HIV) in different variations. CTS was deleted or inserted in accordance with the scheme shown above.
Control
DMSO
Aphidicolin
Add virus 0hrs
OH
HO
CH3
OH
OH
+Seed cells −24hrs Add drug 24hrs FCM +48hrs
CH3
Figure 3:The timescale representation of the transduction experiments with aphidicolin substance to stop a cell cycle in G
1
/S phase. DMSO
was added to the A549 cells for a toxicity evaluation and as a solvent for the drug.
3. Results and Discussion
To be functional, the retroviral system for gene therapy must
comprise two principal elements, these being as truncated
viral backbones and packaging plasmids. The PFV system
therefore includes the Cas I and Cas II (cPPT) backbone
elements as a part of pMD9 and pCIgag2, pCpol-2, and
pCenv-1 packaging plasmids. On the contrary, the HIV sys-
tem comprises the𝜓 packaging signal, ref-responsive element
(RRE), cPPT-CTS, and posttranscriptional cis-acting regula-
tory element (WPRE) as a part of the pWPXL vector together
with psPAX2 (Gag, Pol, rev, and tat) and pMD2.G (VSV-G)
packaging vectors to produce G-glycoprotein pseudotyped
retroviral particles.
To address the question of the influence of cPPT (HIV)
together with the CTS element on the foamy viral cycle, we
compared the cell cycle requirements for efficient cell trans-
duction by the pMD9- and pWPXL-based plasmids, express-
ing the same transgene (eGFP) under control of different pro-
moters (SFFVU3 in pMD6 and EF1-𝛼 in pWPXL) in dividing
and growth-arrested (G
1
/S) A549 cells. Although there are
the previously published reports that have already focused
on the cell cycle aspects of retroviral infection [39, 40],
the investigation is the first direct attempt to assess the role of
cPPTmodifications for the two genera of viruses: lentiviruses
(HIV-1) and spumaviruses (PFV).
The analysis of the viral transduction rates revealed that
both untreated or DMSO-treated cells experienced minor
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Figure 4:The summarized statistics of retroviral replication efficiency (transduction rate) in the A549 cells. The pMD9-based plasmids were
tested to efficiently transduce dividing and growth-arrested cells (G
1
/S phase of cell cycle).Three conditions were analysed in the experiment:
control (a); DMSO (b); aphidicolin (c). The mean ± SD values from three independent assays are shown.
decreases in transduction rates for the pMD9-based plasmids
with different cPPT modifications in comparison to pMD9
and pWPXL controls (Figures 4(a) and 4(b)). These results
indicated that the productive infection was observed only if
target cells were allowed to pass throughmitosis. On the other
hand, there was a huge difference in the relative transduction
efficiencies of the vectors when the cells were G
1
/S-arrested
for 24 hours after transduction; while the efficiency of
pWPXL was approximately twenty- (pMD9-cPPT (HIV)-
CTS) to fivefold (pMD9-CTS) higher than that of the pMD9-
based vectors (Figure 4(c)). The short inserts, such as CTS
and cPPT (HIV), also displayed an insignificant reduction in
the transduction rates observed in dividing cells. The longer
insert (cPPT (HIV)-CTS) resulted in an almost 50% reduc-
tion in transduction rates compared to the parental vector
controls (Figures 4(a) and 4(b)). One point to note is that the
different promoters directed the eGFP transgene expression
in the vectors. In this regard, it is always inaccurate to
compare the levels of transgene expression under control of
the different promoters (SFFV U3 versus EF1-𝛼).
FV replication strategy differs in many aspects from that
of orthoretroviruses with the structural proteins displaying
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Figure 5: Analysis of pMD9 parental vector and its modification (pMD9-cPPT (HIV)-CTS). Detection of PFV proteins in HEK 293T cells
(a) contransfected with the retroviral vectors was measured quantitatively for Gag/Pol (b) and Gag fractions (p71, p68) (c). The mean ± SD
values from three independent assays are shown. The area is measured in arbitrary units, which are abbreviated as a.u.
many unique functions not found for the corresponding
orthoretroviral proteins. The FV structural proteins, Gag,
Prt-RT, and Env are initially translated in polyprotein forms
that are subsequently cleaved by cellular proteases (Gag and
Prt-RT proteins), while Env polyprotein is cleaved by viral
protease [15]. Interestingly, the protein analysis of the pMD9-
cPPT (HIV)-CTS plasmid compared to its parental form
indicated that the A549 transduction for the modified vector
was reduced when judged by the Gag/Pol decrease in the
HEK 293T cellular lysates (Figures 5(a) and 5(b)). However,
this was offset by a significant increase in the capacity to
encapsidate Gag and Pol, producing a large pool of defective
virus-like particles (Figures 6(a) and 6(b)).
The organization of Gag matrix protein into MA (p17
matrix), CA, (capsid p24), and NC (p6, nucleocapsid) with
distinct cleavage sites observed in HIV-1 is absent in FVs.
The only processing of FV Gag observed in the course of FV
particle morphogenesis in vivo occurs at the C terminus of
themolecule, removing a 3 kDa peptide (p3) and producing a
shortened protein of 68 kDa. However, three internal sec-
ondary cleavage sites have been characterized in vitro that
seem to be important during steps of the FV replication
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Figure 6: Analysis of pMD9 parental vector and its modification (pMD9-cPPT (HIV)-CTS). Detection of PFV proteins in partially purified
viral particles produced by HEK 293T cells (a) contransfected with the retroviral vectors was measured quantitatively for Gag/Pol (b) and
Gag fractions (p71, p68) (c). The mean ± SD values from three independent assays are shown. The area is measured in arbitrary units, which
are abbreviated as a.u.
cycle upon entry into target cells [15]. Thereby, in the 293T
cellular lysates, the domination of the cleaved versions of
Gag (p68) for either the pMD9 or pMD9-cPPT (HIV)-CTS
constructs (Figure 5(c)) was observed. However, the protein
analysis of the particle preparation revealed the prevalence
of an uncleaved Gag fraction (p71) for pMD9, indicating the
incomplete proteolytic cleavage of the FV capsid protein.The
same fractions were detected in equal amounts in partially
purified particles produced by HEK 293T cells and cotrans-
fected with the modified plasmid (Figure 6(c)).
To assess the viral transduction dynamics and viral titre,
the logistic dose-response function was transformed accord-
ing to (1) and (2), to model the experimentally determined
efficiency of the retroviral replication as percentage of eGFP
cells observed in the A549 cells. Both parameters demon-
strated a correlation to the aforementioned data shown in
Figure 4 indicating some decrease of 𝑓(𝑥)td and 𝑓(𝑥)vt in
dividing cells (Figures 7(a), 7(b), 8(a), and 8(b)). Similarly, the
FV inability to transduce at a significant extent the growth-
arrested cells provided very low 𝑓(𝑥)td and 𝑓(𝑥)vt values
(Figures 7(c) and 8(c)).
Overall, the results might be in conflict with a published
report claiming that simian FV vectors can efficiently trans-
duce aphidicolin-treated cells [40]. While the results cannot
rule out strain-specific differences in the vector systems used,
it is highly likely that simian FV vectors require mitosis for
8 The Scientific World Journal
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Figure 7: Dynamic 𝑓(𝑥)td function: logistic dose-response curve to predict andmodel viral infection cycle of retroviral replication efficiency
in the A549 cells.The pMD9-based plasmids were tested to efficiently transduce dividing and growth-arrested cells (G
1
/S phase of cell cycle).
Three conditions were analysed in the experiment: control (a); DMSO (b); aphidicolin (c).
their efficient transduction. Moreover, they require a break-
down of the nuclear envelope for a successful nuclear entry
[39, 41]. Lentiviral vectors also enter the nucleus using specific
nuclear localization signals [8, 42].
It is more complicated that after viral disassembly in a
cytoplasm some retroviral NLS sequences are recognized by
host-cell import factors such as transportins that mediate
nuclear targeting of PICs via the nuclear pore complex
[7]. Several similar sequences are present in HIV-1, most
significantly in the virus integrase [8, 43]. Foamy viral Gag
and Pol proteins also include NLS sequences [38], but they
were recently shown to be nonfunctional [44].
Like HIV-1, PIC formation is also present in FVs before
the transport of double-stranded cDNAof the virus to the cel-
lular chromatin.Therefore, it is an essential part of replication
of FVs [45]. However, the lower transduction efficiency of FV
vectors in growth-arrested cells, in comparisonwith lentiviral
forms, could be due to the fact that the foamy viral NLSs
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Figure 8: Dynamic 𝑓(𝑥)vt function: logistic dose-response curve to predict and model the viral titre.The pMD9-based vectors were tested to
efficiently transduce dividing and growth-arrested cells (G
1
/S phase of cell cycle). Three conditions were analysed in the experiment: control
(a); DMSO (b); aphidicolin (c).
are being partially occluded in PIC [46], showing that PFV
generates 2-LTR circles in nondividing cells. However, foamy
virus vector preparations already contain 2-LTR circles, so
their presence is not useful for monitoring PFV DNA entry
into the nucleus although it is still possible that there are
further functional blocks for successful PFV integration into
a host genome after the nuclear translocation of its DNA.
In addition, some retroviruses (HIV-1) have a tendency
to package some cellular proteins nonspecifically, and DNA
ligase activity has been previously demonstrated for viral
particles [47]. Therefore, these steps might also take place in
intracellular or extracellular FV particles that contain cDNA
molecules. Some studies even detected additional FVLTRcir-
cles by PCR in aphidicolin-arrested but not serum-deprived
cultures [46].There is a possibility that FV vectors use distinct
mechanisms for nuclear import, as both the viral genome and
Gag proteins accumulate near the centrosome/MTOC and
wait for cell division. They then disassemble, releasing PIC
[46].
The presence of cPPT, that serves as a primer for plus-
strand synthesis to produce the HIV-1 “flap” element, has not
been reported so far for FVs. But plus-strand synthesis that
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ultimately leads to the double-stranded cDNA, the molecular
moiety that actually integrates into the host chromatin is a
universal feature of all retroviruses including spumaviruses,
the subfamily of FVs. The mechanism of formation of ds
cDNA in FV might have a different mechanism.
Taken all together, the cell cycle dependences of foamy
virus infection have demonstrated that vectors based on
these viral genomes are not sufficient for specific targeting
of nondividing cells. Nonetheless, the neurotropism of foamy
viruses is worth testing in animal models. Further studies
will be needed to directly compare foamy viral and lentiviral
vectors in preclinical gene therapy experiments anddefine the
nature of the stable FV vector transduction intermediate in
quiescent cells.
4. Conclusion
In the experiments, modified foamy viral vectors showed a
reduction in transduction rates of dividing, especially G
1
/S-
arrested A549 cells in comparison to lentiviral forms. The
findings have confirmed that mitosis is a critical phase in the
cell cycle for FV transduction, whichwas previously observed
by Bieniasz and coauthors as an absence of the FV protein
expression in G
1
/S- and G
2
-arrested cells [22].
From the data, it is clear that foamy viruses are not able
to infect nondividing cells efficiently most likely because of
lower integration efficiency compared to lentiviruses unless
cells are undergoing mitosis. The results are in accordance
with the previous findings of Trobridge and Russell but
are contrary to the observations published by Mergia and
coauthors [32, 40]. Hence, the current study leads to the fact
that foamy viral vectors could be further improved to be
effective in gene therapy to target nondividing cells.
It is shown how foamy viral vectors can infect the A549
cells in dividing and growth-arrested states; cell-type specific
experiments and molecular cloning strategies were included
to clearly demonstrate that HIV-1 cPPT cannot be substituted
for PFV cPPT without loss of functionality. This might be
because the cognate reverse transcription enzyme is required
for recognition of cPPT and CTS sequences. Furthermore,
validated simulation data and curves were provided for the
dynamic FV replication potential.
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